中国现代药物应用
中國現代藥物應用
중국현대약물응용
CHINESE JOURNAL OF MODERN DRUG APPLICATION
2014年
7期
17-18
,共2页
甲巯咪唑%普萘洛尔%甲亢%疗效
甲巰咪唑%普萘洛爾%甲亢%療效
갑구미서%보내락이%갑항%료효
Methimazole%Propranolol%Hyperthyroidism%Clinical efficacy
目的:观察甲巯咪唑联合普萘洛尔治疗甲亢的临床疗效。方法将68例甲亢患者随机分为对照组与观察组,每组各34例,对照组患者采用甲巯咪唑进行治疗;观察组在对照组治疗基础上加入普萘洛尔;两组用药周期均为3个月,治疗后评定疗效。结果观察组临床总有效率为94.12%,明显高于对照组的82.35%,差异具有统计学意义(P<0.05);治疗结束后,观察组患者血清FT3、FT4等甲状腺激素水平均显著低于对照组,差异均具有统计学意义(P<0.05)。结论甲巯咪唑联合普萘洛尔治疗甲亢的疗效显著,可显著降低患者血清FT3、FT4等甲状腺激素水平。
目的:觀察甲巰咪唑聯閤普萘洛爾治療甲亢的臨床療效。方法將68例甲亢患者隨機分為對照組與觀察組,每組各34例,對照組患者採用甲巰咪唑進行治療;觀察組在對照組治療基礎上加入普萘洛爾;兩組用藥週期均為3箇月,治療後評定療效。結果觀察組臨床總有效率為94.12%,明顯高于對照組的82.35%,差異具有統計學意義(P<0.05);治療結束後,觀察組患者血清FT3、FT4等甲狀腺激素水平均顯著低于對照組,差異均具有統計學意義(P<0.05)。結論甲巰咪唑聯閤普萘洛爾治療甲亢的療效顯著,可顯著降低患者血清FT3、FT4等甲狀腺激素水平。
목적:관찰갑구미서연합보내락이치료갑항적림상료효。방법장68례갑항환자수궤분위대조조여관찰조,매조각34례,대조조환자채용갑구미서진행치료;관찰조재대조조치료기출상가입보내락이;량조용약주기균위3개월,치료후평정료효。결과관찰조림상총유효솔위94.12%,명현고우대조조적82.35%,차이구유통계학의의(P<0.05);치료결속후,관찰조환자혈청FT3、FT4등갑상선격소수평균현저저우대조조,차이균구유통계학의의(P<0.05)。결론갑구미서연합보내락이치료갑항적료효현저,가현저강저환자혈청FT3、FT4등갑상선격소수평。
Objective To observe the clinical effect of methimazole combined with propranolol in the treatment of hyperthyroidism. Methods 68 patients with hyperthyroidism were randomly divided into control group and observation group, 34 cases in each group, the control group were treated by methimazole;and on this basis, the observation group was treated with propranolol for 3 months, 10mg/times. The clinical efficacies of the two groups were evaluated after the treatment. Results The clinical total effective rate of the observation group was 94.12%, and the clinical total effective rate of the observation group was 82.35%, the difference of the two groups was significant (P<0.05);after the treatment, the serum level of FT3, FT4 in the observation group were significantly lower than those in the control group, the difference of the two groups was significant (P<0.05). Conclusion The clinical efficacy of methimazole combined with propranolol in treatment of hyperthyroidism was significant, the treatment can significantly reduce t the serum level of FT3, FT4 in the patients with hyperthyroidism.